Treatment consequence and adverse events of cyclin-dependent kinase 4/6 inhibitors on patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A systematic review and meta-analysis

A meta-analysis of 11 trials including 5,572 patients found that CDK4/6 inhibitors combined with endocrine therapy improved progression-free survival, overall survival, objective response rate, and clinical benefit rate in patients with HR+ HER2- metastatic breast cancer and reduced progressive disease. Hematologic toxicities, liver function abnormalities, and venous thromboembolism were the most common toxicities.